Navigation Links
Healthcare VC Dr. Dinesh Patel to serve on Tute Genomics Board of Directors
Date:11/5/2013

SALT LAKE CITY, Nov. 5, 2013 /PRNewswire-iReach/ -- Dinesh Patel, PhD, co-founder of vSpring Capital (now Signal Peak Ventures), has joined the board of directors for Utah-based Tute Genomics, founded in 2012.  Tute is a professional grade, cloud-based application for the rapid and cost-effective analysis of entire human genomes for healthcare & biomedical research. Tute Genomics comes at a time when the current pace of interpretation of genomic data cannot keep up with the increasing volume of big data that is flooding hospitals & research institutions, calling for a system to analyze these data fast enough to infer the biological insights needed to stay ahead and guide decision-making.   This is the nature of Tute's business and is aligned well with Dr. Patel's knowledge base and skill set.

(Photo:  http://photos.prnewswire.com/prnh/20131105/MN10545)

Dr. Patel brings with him decades of experience which, combined with his belief in the mission of Tute Genomics, are sure to provide a great advantage to the growing company.  Dr. Patel has had leading roles at several life sciences companies. From 1985 to 1999, Dr. Patel served as Co-Founder, Chairman of the Board of Directors and President of TheraTech, Inc., a biotechnology company which he took public and eventually sold  for $350 million to Watson Pharmaceuticals. From 1999 to 2004 he was the Founder, Chairman, and President of Ashni Naturaceuticals, Inc., a company that specializes in the research, development and marketing of clinically tested and patent-protected nutraceutical products. Prior to Signal Peak Ventures, Dr. Patel was an active angel investor in over 20 biotech and technology companies.

Dr. Patel also served on the board of Mediconnect Global, a worldwide leader in medical record retrieval, digitization, and one of the largest cloud-based health information exchanges. In March 2012, Mediconnect was acquired by Verisk Analytics (VRSK) for over $377 million.

Dr. Patel serves on several non-profit boards, and has won numerous awards including; 2010 Utah Youth Village Helping Hand Award, 2009 Utah Genius Lifetime Achievement Award, 2006 Utah Technology Council Hall of Fame Inductee, 2006 Ellis Island Medal of Honor, US Small Business Administration's Business Achiever Award, Scientific and Technology Award (State of Utah), Entrepreneur of the Year Award (Mountain West Venture Group) and Scientific and Technology Development Pioneer of Progress Award to name a few. He is also a charter member of The Indus Entrepreneurs (TiE).

Dr. Patel has also served as co-chair of Governor Huntsman's transition and he is the Chairman of the USTAR Governing Authority board.  He is a member of the Life Sciences and Management Board at the University of Pennsylvania and on the National Advisory Board for the University of Michigan's Technology Transfer Office.

Of his new role with Tute, Dr. Patel is excited to be a part of this promising company and states "Tute Genomics provides a unique and valuable solution to analyzing and understanding the human genome, and will play an important role in advancing personalized medicine."

About Tute Genomics:

Tute Genomics is a cloud-based clinical genome interpretation engine that is secure, robust, professional grade, and has the ability to analyze and annotate personal genomes in a rapid and cost-effective way.  Whole genome sequencing is transforming research & medicine. Researchers and laboratories are getting flooded with high-throughput genetics data sets, but the ability to infer biological insights and guide decision making lag behind significantly. There is an urgent need for tools to analyze genetic variants from personal genomes in research and in clinical settings. Tute Genomics is solving this problem with a web-based clinical genome interpretation engine.  To learn more about Tute Genomics, please go to www.tutegenomics.com

About Dinesh Patel:

Born and raised in Zambia, Africa, Dr. Patel received his bachelor's degree in Pharmacy at Gujarat University located in Ahmedabad, Gujarat, India.  He earned his master's degree from the Philadelphia College of Pharmacy and his Ph.D. in Physical Pharmacy from the University of Michigan. Dr. Patel led the firm's investments in Altea Therapeutics, Axial, Exagen, Inflabloc, Protolex, Q Therapeutics, Zars and Salus Therapeutics which was acquired by Genta (NASDAQ: GNTA) for $30 million.

Media Contact: Lynn Dakoulas, Tute Genomics, 8017104035, lynn@tutegenomics.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Tute Genomics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
8. ViroPharma to Participate in Two December Healthcare Investor Conferences
9. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/9/2016)... Paris Police Prefecture and ... ensure the safety of people and operations in several locations ... Teleste, an international technology group specialised in broadband ... its video security solution will be utilised by ... across the country. The system roll-out is scheduled for the ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
Breaking Biology News(10 mins):